What's Happening?
A new white paper from the industry group BioPhorum outlines the importance of technical assurance for artificial intelligence in the pharmaceutical sector. As AI becomes integral to healthcare and pharmaceutical operations, the need for evidence-based
trust in AI systems is emphasized. The paper, titled 'A Practical Guide to Technical Assurance for AI,' highlights the necessity of structural, process, technical, and cultural assurance to ensure AI systems are reliable and safe. It stresses the importance of empirical evidence in model performance, robustness, bias behavior, and explainability, moving beyond early success stories to a more rigorous assurance framework.
Why It's Important?
The integration of AI into the pharmaceutical industry holds significant potential for improving efficiency and innovation. However, the high-stakes nature of healthcare requires robust assurance frameworks to prevent failures that could have serious consequences. By establishing a comprehensive assurance architecture, the industry can ensure AI systems are not only compliant but also safe and effective in real-world applications. This development is crucial for maintaining trust in AI technologies and ensuring they meet regulatory standards, ultimately benefiting patients and healthcare providers by enhancing the quality and reliability of AI-driven solutions.
What's Next?
The guide suggests that pharmaceutical companies should integrate technical assurance early in the AI lifecycle, from concept to deployment and ongoing monitoring. This involves building cross-functional teams, maintaining auditable assurance registers, and embedding assurance requirements into vendor contracts. As AI regulation evolves, companies that master technical assurance will be better positioned to develop scalable and defensible AI systems. The focus will be on ensuring data quality, model performance, and bias control, with continuous monitoring to adapt to changing conditions and maintain system integrity.
